Pricing Log in Create free account
Saturday 17 October 2026 Export STE’s income statement to Excel — free account

STERIS plc

STE Healthcare Medical Devices

STERIS plc’s revenue for fiscal 2026 (year ended March 2026) was $5.9 billion, up 8.73% from fiscal 2025. In the quarter to June 2026, revenue grew 7.30%, EPS grew 13.9%, free cash flow fell 14.4% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

222.66 1.67 −0.74%
Market cap
$21.9B
P/E
27.1×
Fwd P/E
23.6×
Dividend yield
1.16%
F-score
9/9
Altman Z
5.10
Beneish M
−2.68
Dividend safety
86/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 9.83
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 3 — — — 1 — — 3 — 1 — —
Insider Ownership 0.44%

Capital & Financial Ratios $m

Market Cap 21,870.00
Revenue 6,037.50
Net Income 808.10
Free Cash Flow 936.00
Net Debt 1,411.30
Current Ratio 1.91 (at or above 1.5: strong)
Debt/Equity 0.26 (at or below 0.5: strong)
P/E ratio 27.12
Fwd P/E 23.60
P/S ratio 3.60
P/B ratio 3.01
Past 5Y EPS Growth 11.36%
This Y EPS Growth 10.19%
Next Y EPS Growth 9.30%
Next Y revenue growth 7.35%
Next 5Y EPS Growth 9.81%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.8×, against a ten-year median of 4.5×; over the ten years it ranged from 2.7× in 2016 to 6.9× in 2021.
P/E against its own 10 years 3.67%
10-year low 10-year high
P/S against its own 10 years 29.75%
10-year low 10-year high
P/B against its own 10 years 33.39%
10-year low 10-year high
EV/Sales against its own 10 years 27.53%
10-year low 10-year high
EV/FCF against its own 10 years 5.49%
10-year low 10-year high

Dividends

Payout Ratio 0.32
Annual Dividend Rate 2.58
Annual Dividend Yield 1.16%
total individual payouts
2029 Powerpack
2028 Powerpack
2027 Powerpack
2026 2.43
0.63
0.63
0.69
2025 2.40
0.57
0.57
0.63
0.63
2024 2.18
0.52
0.52
0.57
0.57
2023 1.98
0.47
0.47
0.52
0.52
2022 1.80
0.43
0.43
0.47
0.47
2021 1.66
0.40
0.40
0.43
0.43
2020 1.54
0.37
0.37
0.40
0.40
2019 1.42
0.34
0.34
0.37
0.37
2018 1.30
0.31
0.31
0.34
0.34
2017 1.18
0.28
0.28
0.31
0.31
2016 1.06
0.25
0.25
0.28
0.28
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 207 172 440 482
Receivables 1,008 1,044 1,093 1,013
Inventory 675 581 632 712
Other 805 — — —
2,869 2,001 2,395 2,446
2024 2025 2026 Q'26
Payables 252 281 339 344
ST’ Debt 86 125 119 243
Other 64 616 687 696
931 1,022 1,145 1,283

Compound Annual Growth %

10y 5y 3y
Sales 10.24% 13.82% 9.38%
Cash Flow 18.07% 14.23% 21.01%
Earnings 21.59% 14.51% 94.07%
Book Value 9.00% 13.09% 5.74%

Revenue $m

Jun Sep Dec Mar Year
’26 1,493 — — — —
’26 1,391 1,460 1,496 1,588 5,936
’25 1,280 1,329 1,371 1,481 5,460
’24 1,183 1,238 1,298 1,419 5,139
’23 1,156 1,201 1,216 963 4,536
’22 968 1,197 1,209 849 4,223
’21 669 756 809 874 3,108
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 367 — — — —
’26 420 288 298 335 1,341
’25 304 251 333 261 1,148
’24 281 146 291 255 973
’23 232 104 206 216 757
’22 97 171 244 172 685
’21 134 162 206 188 690
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 280 — — — —
’26 327 201 210 245 983
’25 196 149 244 199 787
’24 215 70 172 163 620
’23 117 21 125 147 410
’22 41 95 165 99 399
’21 67 118 152 113 451
Fiscal quarters ending in the months shown.

EPS $

Jun Sep Dec Mar Year
’26 2.04 — — — —
’26 1.79 1.94 1.96 2.24 7.93
’25 1.46 1.51 1.75 1.48 6.20
’24 1.25 1.16 1.42 (0.01) 3.81
’23 1.10 (3.15) 1.24 1.88 1.07
’22 (0.24) 0.69 1.42 0.52 2.48
’21 1.03 1.23 1.33 1.02 4.63
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 65.27 82.88 100.91 105.69 170.36 159.21 173.21 197.82 200.98 195.14

Analyst estimates 2027–2029

Powerpack
High 93.39 121.67 156.66 196.80 245.82 255.93 254.00 248.24 268.60 269.44
People
People Employees 12,000 12,000 12,000 13,000 13,000 16,422 17,100 18,179 17,787 17,937
Revenue/emp, $m 0.22 0.22 0.23 0.23 0.24 0.26 0.27 0.28 0.31 0.33
Income, $m
Income, $m Revenue 2,613 2,620 2,782 3,031 3,108 4,223 4,536 5,139 5,460 5,936
Gross margin, % 39.28 41.71 42.23 43.55 43.22 44.59 43.66 43.16 44.01 44.25
EBT 185 355 369 499 518 367 680 703 796 1,047
EBT margin, % 7.07 13.55 13.26 16.46 16.65 8.69 15.00 13.68 14.58 17.64
Net income 111 292 305 408 397 243 106 380 616 785
Depreciation 246 178 226 197 219 620 560 570 476 487
Per share, $
Per share, $ Revenue 30.57 30.81 32.90 35.75 36.47 43.30 45.50 52.01 55.37 60.45
Earnings 1.29 3.42 3.59 4.81 4.66 2.50 1.07 3.83 6.24 7.97
Cash flow 4.96 5.38 6.38 6.97 8.09 7.02 7.59 9.85 11.64 13.66
Capex (1.97) (1.92) (2.18) (2.48) (2.80) (2.93) (3.48) (3.57) (3.66) (3.65)
Free cash flow 3.00 3.46 4.20 4.48 5.29 4.09 4.11 6.28 7.98 10.01
Book value 32.88 37.84 37.67 40.32 45.67 67.10 61.05 63.92 67.10 73.29
Shares, m 85 85 85 85 85 98 100 99 99 98
Valuation, ×
Valuation, × P/E 54.27 26.54 35.30 29.10 41.05 99.91 175.49 57.71 36.38 27.78
P/S 2.27 2.95 3.87 3.92 5.22 5.58 4.20 4.25 4.09 3.66
P/B 2.11 2.41 3.38 3.47 4.17 3.60 3.13 3.46 3.38 3.02
EV/Sales 2.73 3.38 4.22 4.20 5.69 6.23 4.84 4.83 4.44 3.91
EV/FCF 27.86 30.09 33.04 33.45 39.21 65.97 53.57 40.03 30.77 23.61
Cash, $m
Cash, $m Operating cash flow 424 458 540 591 690 685 757 973 1,148 1,341
Capex (168) (163) (184) (210) (239) (286) (347) (353) (361) (358)
Free cash flow 256 294 355 380 451 399 410 620 787 983
Balance, $m
Balance, $m Working capital 636 591 589 720 634 957 1,150 1,938 979 1,250
Total debt 1,478 1,316 1,183 1,171 1,674 3,088 3,079 3,206 2,044 1,932
Net debt 1,195 1,114 963 851 1,453 2,740 2,870 2,999 1,872 1,492
Shareholders’ equity 2,810 3,217 3,186 3,418 3,891 6,545 6,087 6,315 6,616 7,197
Returns, %
Returns, % ROA 2.14 5.75 5.91 7.75 6.61 2.71 0.96 3.46 5.80 7.49
ROIC 3.53 5.77 6.19 7.86 6.41 3.22 5.52 5.61 6.38 7.92
ROE 3.76 9.65 9.49 12.35 10.87 4.67 1.69 6.10 9.51 11.33
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

STERIS plc vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DXCM DexCom, Inc. $33.1B 33.2× 29.8× +13.08% (above 0%: growing) +41.30% (above 0%: growing) −11.68% (below 0%: shrinking) 63.44% 24.33% Compare
GEHC GE HealthCare Technologies Inc. $31.8B 16.0× 14.4× +5.75% (above 0%: growing) +16.98% (above 0%: growing) +750.00% (above 0%: growing) 41.17% 13.96% Compare
PHG Koninklijke Philips N.V. $24.9B 18.8× 11.2× +2.94% (above 0%: growing) +56.67% (above 0%: growing) +49.74% (above 0%: growing) 49.31% 13.99% Compare
STE STERIS plc $21.9B 27.1× 23.6× +7.30% (above 0%: growing) +13.89% (above 0%: growing) −14.36% (below 0%: shrinking) 45.84% 19.15%
ZBH Zimmer Biomet Holdings, Inc. $18.0B 23.0× 17.7× +4.80% (above 0%: growing) +33.77% (above 0%: growing) +13.05% (above 0%: growing) 70.81% 14.98% Compare
PEN Penumbra, Inc. $12.7B 78.4× 63.5× +14.90% (above 0%: growing) −24.79% (below 0%: shrinking) +10.81% (above 0%: growing) 67.93% 10.52% Compare
SNN Smith & Nephew SNATS, Inc. $12.2B 35.4× 18.6× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00% Compare
GMED Globus Medical, Inc. $10.6B 19.3× 20.3× +5.94% (above 0%: growing) −25.33% (below 0%: shrinking) +571.30% (above 0%: growing) 69.42% 23.10% Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 43.7× — −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
Median of peers $15.3B 28.1× 18.6× +5.85% +18.00% +31.40% 65.68% 13.97%

All 149 Medical Devices stocks →

STE metrics, ten years each

STERIS plc (STE) key facts

  • Strength: STERIS plc’s revenue for fiscal 2026 (year ended March 2026) was $5.9 billion, up 8.73% from fiscal 2025.
  • Strength: Net income was $785.1 million, or $7.97 per share (basic), a net margin of 13.2%.
  • STERIS plc (STE) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, STE traded at $222.66, a market capitalization of $21.9 billion.
  • At that price the stock trades at 27.1× trailing-twelve-month earnings and 3.6× sales; its P/E is higher than 4% of its own readings over the past ten years.
  • STERIS plc pays an annual dividend of $2.58 per share, a yield of 1.16%, with a payout ratio of 31.5%.
  • Return on equity was 11.3% and debt-to-equity 0.26.
  • Its Piotroski F-score is 9 out of 9 and its Altman Z-score is 5.10 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

STERIS plc (STE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/STE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com